123I-Ioflupane/SPECT binding to striatal dopamine transporter (DAT) uptake in patients with Parkinson's disease, multiple system atrophy, and progressive supranuclear palsy

A. Antonini, R. Benti, R. De Notaris, S. Tesei, A. Zecchinelli, G. Sacilotto, N. Meucci, M. Canesi, C. Mariani, G. Pezzoli, P. Gerundini

Research output: Contribution to journalArticle

Abstract

We used SPECT and the tracer 123I-Ioflupane to measure dopamine transporter (DAT) binding in the caudate nucleus and the putamen of 70 patients with Parkinson's disease (PD), 10 with multiple system atrophy (MSA-P type), and 10 with progressive supranuclear palsy (PSP). Data were compared with 12 age-matched control subjects. We found significant reductions in mean striatal values in all three forms of parkinsonism. However, decrements were significantly greater in PSP (0.51±0.39, p

Original languageEnglish
Pages (from-to)149-150
Number of pages2
JournalNeurological Sciences
Volume24
Issue number3
DOIs
Publication statusPublished - Oct 2003

ASJC Scopus subject areas

  • Neuroscience(all)
  • Clinical Neurology

Fingerprint Dive into the research topics of '<sup>123</sup>I-Ioflupane/SPECT binding to striatal dopamine transporter (DAT) uptake in patients with Parkinson's disease, multiple system atrophy, and progressive supranuclear palsy'. Together they form a unique fingerprint.

Cite this